# US 12,599,644 B2 · Treatment of coronavirus infection with Flt3 receptor interacting lectin (FRIL)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,599,644 B2
- Document ID: US12599644B2
- Status: Granted
- Kind: B2
- Application number: 17/922,977
- Filed: 2021-05-06
- Published: 2023-11-02
- Granted: 2026-04-14
- Earliest claimed: 2020-05-07
- Assignees: Academia Sinica
- Applicants: Academia Sinica
- Inventors: Che Ma; Jia-Tsrong Jan
- Web page: https://patentgrep.com/patent/US12599644B2

## CPC

- A61K 36/896: Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K 38/179: {for growth factors; for growth regulators}
- A61K 38/45: Transferases (2)
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 31/14: for RNA viruses
- C12Y 207/10001: Receptor protein-tyrosine kinase (2.7.10.1)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

Disclosed herein is a method for treating or preventing a coronavirus infection, which comprises administering to a subject in need thereof an effective amount of a composition comprising Flt3 receptor interacting lectin (FRIL) from Lablab purpureus. Also disclosed is a pharmaceutical composition comprising a pharmaceutically acceptable excipient, a Lablab purpureus FRIL, and an additional therapeutic agent.

## Claims

### Claim 1

A method for treating a coronavirus infection, comprising administering to a subject in need thereof an effective amount of a composition comprising Flt3 receptor interacting lectin (FRIL) from Lablab purpureus, wherein the FRIL comprises SEQ ID NO: 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the coronavirus is severe acute respiratory syndrome coronavirus-2 (SARS-COV-2) or severe acute respiratory syndrome coronavirus (SARS-COV).

### Claim 3 (depends on 1)

The method of claim 1, wherein the FRIL is a native protein isolated from Lablab purpureus.

### Claim 4 (depends on 1)

The method of claim 1, wherein the FRIL is a recombinant or synthetic protein.

### Claim 5 (depends on 1)

The method of claim 1, wherein the FRIL is a tetrameric protein in a tetrahedral configuration.

### Claim 6 (depends on 1)

The method of claim 1, wherein the FRIL comprises a region having SEQ ID NO: 2, and a region having SEQ ID NO: 3.

### Claim 7 (depends on 1)

The method of claim 1, wherein the FRIL binds to one or more glycans on the coronavirus.

### Claim 8 (depends on 1)

The method of claim 1, wherein the subject is suffering from or susceptible to coronavirus infection, or suspected of being infected with a coronavirus.

### Claim 9 (depends on 1)

The method of claim 1, wherein the composition further comprises a second therapeutic agent.

### Claim 10 (depends on 9)

The method of claim 9, wherein the second therapeutic agent is selected from the group consisting of an anti-inflammatory drug, an anti-viral drug, a vaccine for coronavirus, antibiotics, a dietary supplement and palliative therapy to treat coronavirus infection.

### Claim 11 (depends on 10)

The method of claim 10, wherein the second therapeutic agent is an anti-viral drug.

### Claim 12 (depends on 11)

The method of claim 11, wherein the anti-viral drug is selected from the group consisting of ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine, remdesivir (GS-5734), favipiravir (T-705), interferon, adefovir, tenofovir, acyclovir, brivudine, cidofovir, fomivirsen, foscarnet, ganciclovir, amantadine, rimantadine and zanamivir.

### Claim 13 (depends on 1)

The method of claim 1, wherein the composition is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly or intracranially.